JW0061
- Phase 1 GFRA1 agonist · JW Pharmaceutical · trial NCT07514780
GFRA1 agonist aimed at follicle stem cells, in a first-in-human (Phase 1) safety study
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research
— no indexed studies mention JW0061 in a hair context yet
All on OpenAlex →Posts 10
- Why is nobody studying the difference between donor and balding hair?
- JW Pharmaceutical shows superiority of 'JW0061' in hair growth over existing treatments in US
- Is there ANY new medications being worked on?
- Most Promising Future Hair Loss Treatments In 2026
- What are the most promising treatments that are up and coming?
- Is there a way to REDUCE SENSITIVITY to dht rather reducing dht itself??
- Hair longevity with finasteride/minoxidil
- Status update on upcoming treatments
- Cure/better treatment options in the future
- (Serious) News and discussion on potential treatments